Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market - Regional Insights
Turkey is expected to hold a dominant position in the Middle East and Turkey immune Thrombocytopenic Purpura (ITP) Treatment Drugs market owing to strategic collaborations by key players in order to distribute their products all over the country, which, in turn, is aiding the growth of the Turkey immune thrombocytopenia purpura market. For instance, in January 2019, Rigel Pharmaceuticals, Inc. collaborated and entered into an exclusive license and supply agreement with Spain-based Grifols S.A, to commercialize fostamatinib disodium hexahydrate in all potential indications in Europe and Turkey.
Saudi Arabia is expected to foresee a rapid growth in the Middle East and Turkey immune Thrombocytopenic Purpura (ITP) Treatment Drugs market. Saudi Arabia is expected to gain momentum owing to increasing prevalence of immune thrombocytopenia purpura among pediatric population in the country over the forecast period. For instance, according to a study report by King Khalid University of Saudi Arabia, published in December 2014, around 86% of pediatric cases of ITP are under the age of 6. As per the same source, 58% of the pediatric patients are female.
Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients